GlassScriptPhysician profile
Brenda Lyn Axmann
NPI 1669421632
$10,285.47
in general payments reported to CMS, 2019-2025
33 companies · $623 in 2025
The $623 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $305 · 2021: $448 · 2022: $542 · 2023: $7,069 · 2024: $726 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Food and Beverage: $2,475 · Travel and Lodging: $1,421 · Gift: $22.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Food and Beverage | $2,475.23 |
| Travel and Lodging | $1,420.75 |
| Gift | $22.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,612.03 | 2023-2024 | Davinci Xi, Da Vinci Surgical System |
| Abbvie INC. | $475.68 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $469.98 | 2022-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $390.04 | 2019-2021 | |
| Pfizer INC. | $348.08 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $317.31 | 2022-2025 | |
| Millicent US INC | $298.12 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Exeltis, USA INC. | $238.38 | 2019-2025 | Slynd |
| Amgen INC. | $121.20 | 2019-2025 | Evenity, Prolia, Prolia |
| Sumitomo Pharma America, INC. | $99.40 | 2023-2024 | Myfembree |
| Organon LLC | $99.36 | 2021-2025 | Nexplanon |
| Myriad Women'S Health, INC. | $84.79 | 2023 | Myrisk |
| Myovant Sciences INC. | $77.39 | 2021-2022 | |
| Duchesnay USA Incorporated | $63.35 | 2019 | |
| Merck Sharp & Dohme LLC | $57.69 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $56.13 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.74 | 2019-2025 | |
| Exact Sciences Corporation | $44.97 | 2023-2025 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $44.96 | 2021 | |
| Coopersurgical, INC. | $43.75 | 2024 | Supercut Hysterectomy Scissors |
| Scynexis, INC. | $41.96 | 2022 | |
| Amag Pharmaceuticals, INC. | $38.45 | 2019 | |
| Vertical Pharmaceuticals, LLC | $37.57 | 2019 | |
| Currax Pharmaceuticals LLC | $31.93 | 2024-2025 | Contrave, Onzetra Xsail |
| Aspira Women'S Health INC | $21.79 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $20.71 | 2023 | Vivjoa |
| Agile Therapeutics, INC. | $20.49 | 2021 | |
| Meditrina | $20.36 | 2022 | |
| Novum Pharma, LLC | $18.83 | 2019 | |
| Acella Pharmaceuticals, LLC | $17.84 | 2025 | NP Thyroid 60 |
| Hologic Sales and Service, LLC | $15.02 | 2020 | |
| Allergan, INC. | $11.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Axmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.